Industrias Melder revises initial order from
300 kgs to 2 tonnes
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”) a life
sciences corporation focused on developing and commercializing
immune-system improving products for livestock, companion animal
and human applications, is pleased to announce that its North
American purchase order for OxC-beta™ Livestock, placed in March by
Mexico-based Industrias Melder, has been increased from 300 kgs to
2 tonnes. The increase follows the positive results of two dairy
animal tests recently conducted by one of Industrias Melder’s key
customers.
Kym Anthony, C.E.O. of Avivagen, commented, “We are very excited
to announce this increase in the initial sale of OxC-beta™
Livestock to Industrias Melder and we are working to further
formalize a long-term relationship with them. This sale has a
twofold significance. First, it represents a critical step in
bringing OxC-beta™ Livestock to Mexico, a market with annual feed
sales of more than 36 million tonnes.i Second, this is the first
application of OxC-beta in the dairy sector and therefore it
provides crucial commercial validation of the product that other
customers will look to when making purchasing decisions.” Mr.
Anthony further added, “It should also be noted that both these
milestones were spearheaded by our Mexican partner, Mr. Alejandro
Meyenberg, whose help and expertise were instrumental in this
endeavour.”
This significant order comes as the result of two positive tests
of OxC-beta™ Livestock under Mexican commercial dairy production
conditions. Both tests were conducted by a dairy farm that is a
customer of Industrias Melder. The tests ran for 42 days and
evaluated OxC-beta for the ability to improve animal health,
productivity and milk quality. In the first test, conducted with a
group of the farm’s best producing cows, there were improvements in
the both the quantity and quality of milk produced. The largest
impact was a 54% reduction in the farm’s bulk tank milk-somatic
cell count. The somatic cell count of a farm’s bulk milk reservoir
is a widely recognized indicator of milk quality and farms commonly
receive financial incentives or premiums for milk with lower
somatic cell counts. There was also a benefit on animal health as
indicated by reduced somatic cell counts from milk sampled from
individual animals. Of significant note, a large and well known
global dairy processor that purchases the farm’s milk recognized
the farm with three separate financial awards for the improvements
in milk yield, quality, and reduced bacterial levels achieved
during the test.
At the conclusion of the first test a second test was conducted
at the same site on a separate group of cows with chronic health,
productivity and milk quality challenges. The results of the second
test were largely consistent with those observed for the first
trial. Namely, increased milk quality stemming from an improvement
in overall animal health. As in the first test the benefit of using
OxC-beta was most evident on the bulk tank milk-somatic cell count,
which was greatly reduced (67%) during the second test. There was
also an 8% increase in the number of animals categorized as
“healthy” by the attending veterinarian. This was an important
finding given the suboptimal health status of this group of animals
at the beginning of the test.
The successful outcome of these latest tests in Mexico is
consistent with earlier dairy trials in New Zealand and China and
provides yet further evidence of OxC-beta’s benefits for dairy
cattle, in addition to swine, poultry, companion animals and
humans.
About Avivagen
Avivagen is a life sciences corporation focused on developing
and commercializing products for livestock, companion animal and
human applications. By unlocking an overlooked facet of β-carotene
activity, a path has been opened to safely and economically support
immune function, thereby promoting general health and performance
in animals. Avivagen is a public corporation traded on the TSX
Venture Exchange under the symbol VIV and on the OTCQB Exchange in
the U.S. under the symbol VIVXF, and is headquartered in Ottawa,
Canada, based in partnership facilities of the National Research
Council of Canada and Charlottetown, Prince Edward Island. For more
information, visit www.avivagen.com. The contents of the website
are expressly not incorporated by reference in this press
release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen
discoveries about β-carotene and other carotenoids, compounds that
give certain fruits and vegetables their bright colours. Through
support of immune function the technology provides a non-antibiotic
means of promoting health and growth. OxC-beta™ Livestock is a
proprietary product shown to be an effective and economic
alternative to the antibiotics commonly added to livestock feeds.
The product is currently available for sale in the United States,
Philippines, Taiwan, New Zealand, Thailand, Mexico, Australia and
Malaysia.
Avivagen’s OxC-beta™ Livestock product is safe, effective and
could fulfill the global mandate to remove all in-feed antibiotics
as growth promoters. Numerous international livestock trials with
poultry and swine using OxC-beta™ Livestock have proven that the
product performs as well as, and, sometimes, in some aspects,
better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements
that are based upon the current expectations of management.
Forward-looking statements involve risks and uncertainties
associated with the business of Avivagen Inc. and the environment
in which the business operates. Any statements contained herein
that are not statements of historical facts may be deemed to be
forward-looking, including those identified by the expressions
“aim”, “anticipate”, “appear”, “believe”, “consider”, “could”,
“estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”,
“may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”,
“should”, “whether”, “will”, “would” and similar expressions.
Statements set out in this news release relating to the continued
distribution and acceptance of Avivagen’s technology, anticipated
growth in demand for Avivagen’s products, the possibility for
OxC-beta™ Livestock to replace antibiotics in livestock feeds as
well as fill a critical need for health support in certain
livestock applications where antibiotics are precluded, the size of
market opportunities and the potential for a longer term
relationship with Industrias Melder are all forward-looking
statements. These forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
or events to differ materially from current expectations. For
instance, these initial orders may not result in new orders for
Avivagen’s products, demand for Avivagen’s products may not
continue to grow and could decline, Avivagen’s products may not
gain market acceptance or regulatory approval in new jurisdictions
or for new applications and may not be widely accepted as a
replacement for antibiotics in livestock feeds, new market access
may not occur in the timeline or manner expected by Avivagen, the
market opportunities may not be as large as Avivagen anticipates
and a longer term relationship with Industrias Melder may not be
achieved due to many factors, many of which are outside of
Avivagen’s control. Trial results described above may not be
indicative of anticipated results of using Avivagen’s products in
all cases. Readers are referred to the risk factors associated with
the business of Avivagen set out in Avivagen’s most recent
management’s discussion and analysis of financial condition
available at www.SEDAR.com. Except as required by law, Avivagen
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of
Avivagen Inc.
i
https://www.alltech.com/press-release/2019-alltech-global-feed-survey-estimates-world-feed-production-increased-3-percent
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200520005080/en/
Avivagen Inc. Drew Basek Director of Investor Relations 100
Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com Kym Anthony Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office
Phone: 613-949-8164 Website: www.avivagen.com
Avivagen (TSXV:VIV)
Historical Stock Chart
Von Jan 2025 bis Feb 2025
Avivagen (TSXV:VIV)
Historical Stock Chart
Von Feb 2024 bis Feb 2025